Skip to Content

Somapacitan-beco Side Effects

Applies to somapacitan-beco: subcutaneous solution

Metabolic

Elevated phosphate and creatine phosphokinase occurred intermittently and were non-progressive.[Ref]

Very common (10% or more): Elevated phosphate (17.5%)

Common (1% to 10%): Elevated creatine phosphokinase, blood creatinine kinase increase, weight increased

Frequency not reported: Glucose intolerance, diabetes mellitus, fluid retention[Ref]

Nervous system

Common (1% to 10%): Sleep disorder, dizziness

Frequency not reported: Intracranial hypertension[Ref]

Endocrine

Common (1% to 10%): Adrenal insufficiency, hypoadrenalism, hypothyroidism[Ref]

Gastrointestinal

Common (1% to 10%): Dyspepsia, vomiting

Frequency not reported: Pancreatitis[Ref]

Hypersensitivity

Frequency not reported: Severe hypersensitivity[Ref]

Musculoskeletal

Very common (10% or more): Back pain (10%)

Common (1% to 10%): Arthralgia[Ref]

Hematologic

Common (1% to 10%): Anemia[Ref]

Oncologic

Frequency not reported: Neoplasms[Ref]

Other

Common (1% to 10%): Peripheral edema

Frequency not reported: Increased mortality in patients with acute critical illness[Ref]

Cardiovascular

Common (1% to 10%): Hypertension[Ref]

Local

Frequency not reported: Lipohypertrophy, lipoatrophy[Ref]

Respiratory

Common (1% to 10%): Tonsillitis[Ref]

References

1. "Product Information. Sogroya (somapacitan)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

More about somapacitan-beco

Consumer resources

Other brands: Sogroya

Professional resources

Related treatment guides